Carmell Therapeutics Corporation Statistics
Share Statistics
Carmell Therapeutics Corporation has 20.91M shares outstanding. The number of shares has increased by -9.43% in one year.
| Shares Outstanding | 20.91M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 13.47M |
| Failed to Deliver (FTD) Shares | 523 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 505.09K, so 2.42% of the outstanding shares have been sold short.
| Short Interest | 505.09K |
| Short % of Shares Out | 2.42% |
| Short % of Float | 3.75% |
| Short Ratio (days to cover) | 0.04 |
Valuation Ratios
The PE ratio is -2.72 and the forward PE ratio is null.
| PE Ratio | -2.72 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.7 |
| P/FCF Ratio | -5.01 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Carmell Therapeutics Corporation.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.63, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.63 |
| Quick Ratio | 1.63 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 4.95 |
| Cash Flow / Debt | -6.48 |
| Interest Coverage | -5.87 |
Financial Efficiency
Return on equity (ROE) is -0.62% and return on capital (ROIC) is -18.5%.
| Return on Equity (ROE) | -0.62% |
| Return on Assets (ROA) | -0.24% |
| Return on Capital (ROIC) | -18.5% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.72M |
| Employee Count | 9 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -760.16K |
| Effective Tax Rate | 0.05 |
Stock Price Statistics
The stock price has increased by -86.08% in the last 52 weeks. The beta is 0.31, so Carmell Therapeutics Corporation's price volatility has been higher than the market average.
| Beta | 0.31 |
| 52-Week Price Change | -86.08% |
| 50-Day Moving Average | 0.31 |
| 200-Day Moving Average | 1.14 |
| Relative Strength Index (RSI) | 59.57 |
| Average Volume (20 Days) | 10.93M |
Income Statement
| Revenue | n/a |
| Gross Profit | -124.79K |
| Operating Income | -5.22M |
| Net Income | -15.45M |
| EBITDA | -15.19M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.46 |
Balance Sheet
The company has 2.91M in cash and 2.14M in debt, giving a net cash position of 776.01K.
| Cash & Cash Equivalents | 2.91M |
| Total Debt | 2.14M |
| Net Cash | 776.01K |
| Retained Earnings | -58.50M |
| Total Assets | 2.44M |
| Working Capital | -4.29M |
Cash Flow
In the last 12 months, operating cash flow was -8.35M and capital expenditures -30.47K, giving a free cash flow of -8.38M.
| Operating Cash Flow | -8.35M |
| Capital Expenditures | -30.47K |
| Free Cash Flow | -8.38M |
| FCF Per Share | -0.76 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CTCX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -297.96% |
| FCF Yield | -81.61% |
Analyst Forecast
Currently there are no analyst rating for CTCX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -52.05 |
| Piotroski F-Score | 3 |